Shares of Biofrontera, a dermatology-focused biopharmaceutical company, saw a boost after announcing a resolution to an ongoing dispute with pharmaceutical company Maruho. In a securities filing released on Wednesday, Biofrontera disclosed that it had entered into a confidential settlement agreement and share transfer agreement with Maruho.
The dispute between the two companies stemmed from a 2019 deal, wherein Biofrontera sought to avoid repaying $7.3 million in startup costs to Maruho. Biofrontera initiated arbitration proceedings against Maruho in the International Chamber of Commerce, seeking a declaration that it was not obligated to repay the funds.
Under the terms of the settlement, Biofrontera will be relieved of its obligations to repay the $7.3 million and any profit-sharing payments associated with products acquired under the 2019 agreement. In return, Biofrontera will transfer over 5.4 million shares of its stock to Maruho.
This development has had a positive impact on Biofrontera’s shares, with an increase of 5.5% in early trading, reaching $2.85. It is worth noting that the stock was trading at over $17 per share just a year ago.
This resolution marks an important milestone for both companies, putting an end to the dispute and allowing them to move forward without any remaining obligations or outstanding issues.
Leave a Reply